Suhayl Dhib-Jalbut

Title: Suhayl Dhib-Jalbut: Innovator in Autoimmune Disease Treatment

Introduction

Suhayl Dhib-Jalbut is a prominent inventor based in Princeton, NJ (US). He has made significant contributions to the field of medicine, particularly in the treatment of autoimmune diseases. With a total of 2 patents, his work focuses on improving therapeutic responses for patients suffering from conditions such as multiple sclerosis.

Latest Patents

Dhib-Jalbut's latest patents include innovative methods for treating subjects afflicted with autoimmune diseases. One notable patent describes a method that utilizes predictive biomarkers to assess clinical responses to glatiramer acetate therapy in multiple sclerosis. This method involves administering a pharmaceutical composition containing glatiramer acetate and a pharmaceutically acceptable carrier. The process includes determining whether the subject is a responder or a hypo-/non-responder to the treatment by measuring specific biomarkers in the blood. These biomarkers include IL-10, IL-17, IL-18, TNF-α, BDNF, and caspase-1 concentrations, among others. The results are then compared to reference values to guide treatment decisions.

Career Highlights

Suhayl Dhib-Jalbut has established a successful career in the pharmaceutical industry. He is currently associated with Teva Pharmaceutical Industries Limited, where he continues to develop innovative solutions for treating autoimmune diseases. His expertise in the field has positioned him as a key figure in advancing therapeutic strategies.

Collaborations

[This section has been skipped due to space constraints.]

Conclusion

Suhayl Dhib-Jalbut's contributions to the treatment of autoimmune diseases through innovative patent developments highlight his role as a leading inventor in the medical field. His work continues to impact the lives of many patients, paving the way for more effective therapies.